



# VCU

Virginia Commonwealth University  
**VCU Scholars Compass**

---

Internal Medicine Publications

Dept. of Internal Medicine

---

2016

## Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer

Youn Hee Jee

*National Institutes of Health*

Samira M. Sadowsk

*National Institutes of Health*

Francesco S. Celi

*Virginia Commonwealth University, fsceli@vcu.edu*

*See next page for additional authors*

Follow this and additional works at: [http://scholarscompass.vcu.edu/intmed\\_pubs](http://scholarscompass.vcu.edu/intmed_pubs)



Part of the [Medicine and Health Sciences Commons](#)

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

---

Downloaded from

[http://scholarscompass.vcu.edu/intmed\\_pubs/115](http://scholarscompass.vcu.edu/intmed_pubs/115)

This Article is brought to you for free and open access by the Dept. of Internal Medicine at VCU Scholars Compass. It has been accepted for inclusion in Internal Medicine Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact [libcompass@vcu.edu](mailto:libcompass@vcu.edu).

---

**Authors**

Youn Hee Jee, Samira M. Sadowsk, Francesco S. Celi, Liqiang Xi, Mark Raffeld, David B. Sacks, Alan T. Remaley, Anton Wellstein, Electron Kebebew, and Jeffrey Baron

RESEARCH ARTICLE

# Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer

Youn Hee Jee<sup>1</sup>, Samira M. Sadowski<sup>2</sup>, Francesco S. Celi<sup>3</sup>, Liqiang Xi<sup>4</sup>, Mark Raffeld<sup>4</sup>, David B. Sacks<sup>5</sup>, Alan T. Remaley<sup>5</sup>, Anton Wellstein<sup>6</sup>, Electron Kebebew<sup>2</sup>, Jeffrey Baron<sup>1\*</sup>

**1** Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America, **2** Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, **3** Division of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, Virginia, United States of America, **4** Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, **5** Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America, **6** Department of Oncology, Georgetown University Medical Center and Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States of America

\* [jeffrey.baron@nih.gov](mailto:jeffrey.baron@nih.gov)



## OPEN ACCESS

**Citation:** Jee YH, Sadowski SM, Celi FS, Xi L, Raffeld M, Sacks DB, et al. (2016) Increased Pleiotrophin Concentrations in Papillary Thyroid Cancer. PLoS ONE 11(2): e0149383. doi:10.1371/journal.pone.0149383

**Editor:** Soheil S. Dadras, University of Connecticut Health Center, UNITED STATES

**Received:** August 6, 2015

**Accepted:** February 1, 2016

**Published:** February 25, 2016

**Copyright:** This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by the Intramural Research Programs of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Center for Cancer Research, National Cancer Institute (NCI), and the Clinical Center of the National Institutes of Health.

**Competing Interests:** YHJ and JB are co-inventors on a patent application filed by the National Institutes

## Abstract

### Background

Thyroid nodules are common, and approximately 5% of these nodules are malignant. Pleiotrophin (PTN) is a heparin-binding growth factor which is overexpressed in many cancers. The expression of PTN in papillary thyroid cancer (PTC) is unknown.

### Method and Findings

74 subjects (age  $47 \pm 12$  y, 15 males) who had thyroidectomy with a histological diagnosis: 79 benign nodules and 23 PTCs (10 classic, 6 tall cell, 6 follicular variant and 1 undetermined). Fine-needle aspiration (FNA) samples were obtained *ex vivo* from surgically excised tissue and assayed for PTN and thyroglobulin (Tg). Immunohistochemistry (IHC) was performed on tissue sections. In FNA samples, PTN concentration normalized to Tg was significantly higher in PTC than in benign nodules ( $16 \pm 6$  vs  $0.3 \pm 0.1$  ng/mg,  $p < 0.001$ ). In follicular variant of PTC ( $n = 6$ ), the PTN/Tg ratio was also higher than in benign nodules ( $1.3 \pm 0.6$  vs  $0.3 \pm 0.1$  ng/mg,  $P < 0.001$ , respectively). IHC showed cytoplasmic localization of PTN in PTC cells.

### Conclusion

In *ex vivo* FNA samples, the PTN to thyroglobulin ratio was higher in PTCs, including follicular variant PTC, than in benign thyroid nodules. The findings raise the possibility that measurement of the PTN to Tg ratio may provide useful diagnostic and/or prognostic information in the evaluation of thyroid nodules.

of Health that covers the measurement of midkine and pleiotrophin in FNA samples (U.S. Patent Application No. 61/728,624 filed November 20, 2012. HHS Reference: E-016-2013/0-US-01 on assay to measure midkine or pleiotrophin level for diagnosis of a growth. Listed inventors: Baron and Jee). Authors have no other relevant declarations relating to employment, consultancy, patents, products in development or modified products. This did not alter the authors' adherence to PLOS ONE policies on sharing data and materials. Otherwise, the authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

## Introduction

Thyroid nodules occur frequently in the general population with a prevalence of approximately 3–7% for palpable masses [1, 2]. Approximately 5% of thyroid nodules are malignant [3] and the most common histological type is papillary thyroid cancer (PTC) [1]. Two major challenges facing clinicians are to distinguish malignant from benign nodules and to identify those thyroid malignancies that are aggressive [1]. Fine needle aspiration (FNA) cytology represents the primary preoperative diagnostic tool for the evaluation of thyroid nodules [4], but it is inconclusive in up to 30% of patients [5]. In particular, follicular variant PTC is difficult to distinguish from benign follicular lesions by cytology [6, 7].

Pleiotrophin (PTN) and midkine (MDK) are related polypeptide heparin-binding growth factors [8, 9]. PTN and MDK are overexpressed in various human cancers, where they are thought to promote cell survival, proliferation and angiogenesis, contributing to tumor growth [10, 11].

We recently reported that the concentration of MDK in FNA samples is elevated in PTCs compared to benign nodules [12]. In that study, the MDK concentration was normalized to the thyroglobulin (Tg) concentration, which adjusted for tissue content and also enhanced the separation between malignant and benign samples because of lower Tg concentrations in malignant nodules. However, neither the MDK concentration nor the MDK/Tg ratio was elevated in the follicular variant of PTC subgroup [12], limiting the potential diagnostic value of this approach.

PTN was previously reported to be overexpressed in medullary thyroid cancer [13], but the expression of PTN in PTCs has not been investigated. We hypothesized that PTN concentration and PTN/Tg concentration ratio are higher in PTCs than in benign nodules.

## Materials and Methods

### Subjects and sample collection

Seventy-four adult subjects (age  $47 \pm 12$  y, 15 males) with thyroid nodules who underwent thyroidectomy at the National Institutes of Health (NIH) Clinical Center were included in the analysis. Study protocols were approved by National Institute of Diabetes and Digestive and Kidney Disease Institutional Review Board, and all patients provided written informed consent to participate in the study. After the thyroid was excised, selected nodules with surrounding tissues were bisected for procurement and then *ex vivo* FNA was performed by passing a 25-gauge needle into the nodules. The needle was passed 10 to 20 times. No suction was applied. The tissue within the needle was washed out with 0.5 ml of PBS containing 1% BSA. The samples were aliquoted and stored immediately at  $-80^{\circ}\text{C}$  until assay. Multiple *ex vivo* FNA samples (mean, 3.0 samples) were obtained per nodule. We initially attempted to measure PTN in *in vivo* FNA washout samples, after the needle contents had been expelled for cytology, but often found undetectable PTN concentrations, indicating insufficient tissue remaining in the needle (data not shown).

A total of 103 nodules were sampled. Of these, 62 nodule samples were previously assayed for MDK concentration and included in a prior report [12].

### Pleiotrophin Sandwich ELISA Assay

A PTN sandwich ELISA was developed in our laboratory (see [S1 Method](#) for assay details). The intra-assay CV was 6.9% for high concentration (1.3 ng/mL) and 9% for low concentration (0.2 ng/mL). The inter-assay CV was 8.8% at 0.2 ng/mL and 12.3% at 0.6 ng/mL. The limit of detection was 10 pg/mL. There was no cross-reactivity with up to 50 ng/mL of MDK ([S1A Fig](#)). PTN concentrations in PBS containing 1% BSA remained stable in plastic but not glass tubes

over 2 hours at room temperature and with repeated freeze-thaw cycles (S2 Fig). The assay showed good parallelism (S3 Fig).

### Midkine Sandwich ELISA Assay

MDK sandwich ELISA was performed as previously described using a commercial kit (Bioventor, Czech Republic) with modifications [12]. Intra-assay CV was 3.4% at high concentration (0.7 ng/mL) and 5.2% at low concentration (0.25 ng/mL). Inter-assay CV was 12.3% at low concentration. The limit of detection was 0.009 ng/mL. There was no cross-reactivity with up to 50 ng/mL of PTN (S1B Fig).

### Thyroglobulin Assay

50  $\mu$ L of buffer containing thyroid tissue from an FNA needle was diluted 10-fold in normal saline and the concentration of Tg was measured with a chemiluminescent immunometric assay (Immulite 2000XPi, Siemens, UK) according to the manufacturer's instruction and as previously described [12].

### BRAF mutation analysis

DNA was extracted on a Qiacube semiautomated robotic device (Qiagen, Valencia, CA) using either the QIAamp DNA Mini Kit (Qiagen) from 17 FNA washout samples and 6 frozen tissue samples, or the QIAamp DNA FFPE Tissue Kit (Qiagen) for paraffin-embedded tissue sections, according to the instructions of the manufacturer. *BRAF* T1799A (V600E) mutational analysis was performed using the PrimePCR ddPCR mutation detection assay (BIO-RAD, Hercules, CA) on a BIO-RAD QX200 droplet digital PCR (ddPCR) system. Each reaction included 10  $\mu$ L of 2x ddPCR supermix for probes (no dUTP), 1  $\mu$ L of *BRAF* V600E primer/probe mix (FAM), 1  $\mu$ L of *BRAF* wild type primer/probe mix (HEX), and 40–100 ng of genomic DNA. The presence of mutation and the fractional abundance of the mutant allele was determined with QuantaSoft v.1.7 (BIO-RAD).

### Pleiotrophin Immunohistochemistry

Tissues were formalin-fixed, embedded in paraffin, and cut into 5- $\mu$ m-thick sections which were deparaffinized and rehydrated in graded alcohol. For antigen retrieval, sections were placed in citrate buffer at 120°C using a pressurizer cooker for 10 minutes. After blocking with 1.5% normal rabbit serum in Tris-buffered saline and Tween 20 (TBST) for 60 minutes at room temperature, the slides were incubated with a goat polyclonal antibody raised against human PTN (Cat# AF-252-PB, R&D Systems, Minneapolis, MN) at 1:250 dilution in 1.5% serum in TBST overnight at 4°C and then visualized with a biotinylated anti-goat IgG secondary antibody (1:200) using the Vectastain ABC (Goat IgG, PK-6105) and DAB kits (Vector Laboratories, Inc. Burlingame, CA) and counterstained with haematoxylin. Omission of the primary antiserum was used as a negative control and mouse embryo slides were used as a positive control (S5 Fig). Slides were scanned using a ScanScope XT digital slide scanner and viewed using ImageScope software (Aperio Technologies, Inc., Vista, CA).

### Statistical analysis

All FNA samples from each nodule were averaged to obtain a single mean value. After log transformation, the PTN concentration, Tg concentration and PTN/Tg ratio were compared between histological groups using t-tests and ANOVA with post-hoc Bonferroni correction for multiple comparison. The relationship between PTN and Tg was evaluated after log transformation by

general linear model with nodule number as a covariate. The relationship between PTN/Tg and MDK/Tg was evaluated by Pearson regression after log transformation. Statistical analysis was performed using SPSS, version 12 (IBM, NY).

## Results

### Characteristics of subjects and nodules

A total of 103 nodules from 74 subjects (age  $47 \pm 12$  y, 15 males) were studied by *ex vivo* FNA at the time of procurement, immediately after thyroidectomy. Histological examination revealed 23 nodules with PTC (10 classic, 6 tall cell, 6 follicular variant, and 1 undetermined), 1 nodule with medullary thyroid cancer and 79 benign nodules (72 adenomatoid nodules, 4 follicular adenomas and 3 hyperplastic nodules). Characteristics of nodules with PTC are shown in [Table 1](#).

### Association of PTN and Tg concentrations in FNA samples

PTN concentrations were positively associated with Tg concentrations in FNA washout samples from benign nodules (analysis included all individual passes,  $R^2 = 0.04$ ,  $P < 0.001$ , [S4 Fig](#)). Since this correlation likely occurred because both PTN and Tg concentrations in the washout fluid were dependent on the amount of thyroid tissue present in the sample, PTN levels were normalized to Tg levels as PTN/Tg, ng/mg, to correct for the amount of thyroid tissue.

### PTN concentrations and PTN/Tg ratio in ex vivo FNA samples

PTN concentrations in PTC were significantly higher than in benign nodules ( $0.1 \pm 0.01$  vs  $0.05 \pm 0.01$  ng/mL, mean  $\pm$  SEM,  $p < 0.001$ ). PTN concentrations in the subset of follicular variant papillary thyroid cancer (FVPTC) were also higher than in benign nodules ( $0.12 \pm 0.03$  vs  $0.05 \pm 0.01$  ng/mL,  $p < 0.001$ , [Fig 1A](#)).

Tg concentrations were lower in PTC than in benign nodules ( $112 \pm 30$  vs  $926 \pm 88$  ug/mL,  $P < 0.001$ ). In the FVPTC subgroup, Tg concentrations also tended to be lower than in benign nodules but the difference was not statistically significant ( $203 \pm 80$  vs  $926 \pm 88$  ug/mL ng/mL,  $P = \text{NS}$ ). The ratio of PTN to Tg (ng/mg) was higher in PTC than in benign nodules ( $16 \pm 6$  vs  $0.3 \pm 0.1$  ng/mg,  $P < 0.001$ , [Fig 1B and 1E](#)), and also significantly higher in FVPTC than in benign nodules ( $1.3 \pm 0.6$  vs  $0.3 \pm 0.1$  vs ng/mg,  $P < 0.001$ ) ([Fig 1B](#)). PTN/Tg was also elevated in the one nodule containing medullary thyroid cancer (2.9 ng/mg).

Among PTCs, there was no difference in PTN concentrations among classic, tall cell variant and FVPTCs ( $0.09 \pm 0.02$ ,  $0.12 \pm 0.03$  and  $0.12 \pm 0.03$  ng/mL, respectively,  $P = \text{NS}$ ) ([Fig 1C](#)). However, FVPTC had the lowest the PTN/Tg ratios ( $24.5 \pm 11.7$ ,  $42.1 \pm 23.3$  and  $1.3 \pm 0.6$  ng/mg, respectively,  $P = 0.06$ ) ([Fig 1D](#)).

Of 10 benign nodules with the highest PTN/Tg ratio, 2 occurred in patients with Graves' disease (2 of 2 subjects with Graves' disease), 1 in a subject with a follicular adenoma (1 of 4 subjects with follicular adenoma), 1 in a patient with chronic lymphocytic thyroiditis (1 of 3 subjects with chronic lymphocytic thyroiditis), 1 in a benign nodule adjacent to PTC and 5 in benign nodules without other significant histological findings.

The PTN/Tg ratio had no association with nodule size or the presence of lymph node metastasis (data not shown).

### Association between the PTN/Tg and MDK/Tg and bivariate analysis

Both MDK/Tg and PTN/Tg were measured in 22 PTCs and 77 benign nodules. There was no association between the PTN/Tg and MDK/Tg among benign nodules. However, there was a positive correlation between MDK/Tg and PTN/Tg among PTCs ( $R^2 = 0.44$ ,  $P = 0.001$ ) ([Fig 2A](#)).

**Table 1. Characteristics of papillary thyroid cancers (PTCs) studied.**

Diagnosis	Tumor size	Metastasis <sup>a</sup>	MDK/Tg(ng/mg)	PTN/Tg (ng/mg)	BRAF mutation
PTC, classic					
	2.4 cm	5/6 LN	57.7	2.7	+
	0.5 cm		11.8	5.7	-
	0.9 cm		64.1	89.1	+
	3.0 cm		169.9	85.5	+
	1.0 cm		2.4	0.6	-
	4.7 cm	1/1 LN	730.0	54.0	+
	1.0 cm		3.6	4.6	+
	0.7 cm		16.7	0.5	+
	1.8 cm	1/2 LN	NA	0.1	+
	1.6 cm		37.0	1.8	+
PTC, tall cell variant					
	5.0 cm	4/33 LN	262.0	10.7	+
	1.8 cm	1/1 LN	22.4	0.5	+ <sup>c</sup>
	1.5 cm	1/1 LN	0.5	0.4	+ <sup>c</sup>
	1.5 cm	1/1 LN	0.3	12.4	+ <sup>c</sup>
	3.0 cm	2/7 LN	606.0	19.2	+
	2.6 cm		646.0	59.0	+
PTC, follicular variant					
	0.8 cm	1/2 LN	1.5	1.0	+
	1.0 cm		0.6	1.3	- <sup>d</sup>
	0.5 cm		1.7	4.0	-
	0.5 cm		4.5	0.3	-
	1.8 cm		0.2	0.5	-
	1.1 cm		0.9	0.4	- <sup>d</sup>
PTC, undetermined <sup>b</sup>					
	5.0 cm		103.0	2.9	+

<sup>a</sup>LN lymph nodes (number of positive lymph nodes/ total lymph nodes examined).

<sup>b</sup>Histologically, inconclusive but clinically and radiologically malignant

<sup>c</sup>Different nodules from a subject

<sup>d</sup>Different nodules from a subject

doi:10.1371/journal.pone.0149383.t001


A bivariate plot of all nodules with both PTN/Tg and MDK/Tg measured revealed that all PTCs had MDK/Tg greater than 0.2 ng/mL and PTN/Tg greater than 0.13 ng/mL (Fig 2B). Of the 35 nodules that met both these criteria, 23 were malignant (100% of PTC) and 12 were benign (15% of benign nodules), yielding a sensitivity of 100% and a specificity of 85%.

### Association between PTN/Tg ratio and BRAF mutation

Among 23 PTC nodules, 16 had the *BRAF* V600E mutation. The PTN/Tg ratio tended to be higher in *BRAF*-positive than in *BRAF*-negative nodules but the difference did not reach statistical significance ( $21.5 \pm 7.9$  vs  $1.8 \pm 0.8$ ,  $P = 0.095$ ).

### Confirmation of PTN expression using immunohistochemistry

Immunohistochemical staining of tissue sections revealed that PTN immunostaining was more intense in those neoplastic thyroid epithelial cells within the PTCs than in the nearby normal




\*:  $P < 0.001$

**Fig 1. Pleiotrophin (PTN) concentrations and pleiotrophin/thyroglobulin ratios (PTN/Tg) in benign nodules and papillary thyroid cancer (PTC).** Samples were obtained by *ex vivo* fine needle aspiration; PTN and Tg were measured by immunoassay. PTN concentrations (mean  $\pm$  SEM) were higher in PTC (including all subtypes) and in the subset of follicular variant PTC (FVPTC) than in benign nodules (A). Similarly, PTN/Tg was greater in PTC (including all subtypes) and in the subset of FVPTC than in benign nodules (B). PTN concentrations did not differ significantly among classic, tall cell variant, and FVPTC (C). PTN/Tg tended ( $P = NS$ ) to be lower in FVPTC than in other subtypes (D). Scatterplot showing PTN/Tg values of all nodules. Closed symbols, PTC; open symbols, benign nodules (E). Values less than 0.001 are displayed as equal to 0.001.

doi:10.1371/journal.pone.0149383.g001





**Fig 2. Association between PTN/Tg and MDK/Tg ratios among all PTC nodules studied (A).** PTN/Tg and MDK/Tg were positively correlated ( $R^2 = 0.44$ ,  $P = 0.001$ ). **Bivariate analysis of PTN/Tg and MDK/Tg ratios (B).** All PTCs had MDK/Tg greater than 0.2 ng/mL (horizontal dashed line) and PTN/Tg greater than 0.13 ng/mL (vertical dashed line). Values less than 0.001 are displayed as equal to 0.001. Closed circles, PTC; open circles, benign nodules.

doi:10.1371/journal.pone.0149383.g002

thyroid epithelial cells. (Fig 3A–3C). Some scattered stromal cells in the adjacent connective tissue also showed immunohistochemical staining. Within thyroid epithelial cells, the PTN staining was primarily cytoplasmic and perinuclear (Fig 3C).

## Discussion


We found that PTN was measurable in FNA samples obtained *ex vivo* from thyroidectomy specimens and that the PTN concentrations were higher in PTC than in benign nodules. Similarly, the PTN/Tg ratio was greater in PTC than in benign nodules. We initially chose to use Tg as a measure of tissue content. However, we found that the level of Tg in samples from PTC was lower than in samples from benign nodules, suggesting that Tg expression might be lower in malignant cells, consistent with a prior study [14], and therefore Tg may not simply be a measure of tissue content. However, from a pragmatic standpoint, this effect is fortuitous because normalization of PTN to Tg enhanced the separation between malignant and benign samples.

PTN expression by PTCs was confirmed by immunohistochemistry. The immunohistochemical findings suggest that PTN is overexpressed by the neoplastic thyroid epithelial cells themselves, primarily in a perinuclear and cytoplasmic localization as reported in other tissues [15–16]. However, staining for PTN was also observed in the adjacent stromal cells raising the possibility that other cells might also contribute to the elevated PTN measured by ELISA in PTC.

The finding that PTN is elevated in PTC suggests that PTN overexpression may promote growth of PTCs, which has also been suggested for other cancers, such as ovarian [17], pancreatic [18], glioblastoma [19], prostate cancer [20] and breast cancer [21]. For example, in a breast cancer model, PTN overexpression stimulated remodeling of the microenvironment, tumor angiogenesis, and rapid tumor growth [22]. However, in our study, we did not observe an association between the PTN/Tg ratio and the size of the nodules or the presence of lymph node metastasis. We also did not find a significant association between the PTN/Tg ratio and the presence of the BRAF V600E mutation. However, the sample size of our study is insufficient to definitively exclude associations with disease aggressiveness or genetic etiology.

We previously found that the concentration of MDK, a heparin-binding growth factor related to PTN, was higher in PTC than in benign nodules [12]. In the current study, we found that MDK/Tg and PTN/Tg were positively correlated in PTCs. However, one important difference is that, in FVPTC, the PTN/Tg was elevated whereas the MDK/Tg showed values overlapping those of benign nodules. This finding is of particular interest because FVPTC is often difficult to distinguish from benign follicular lesions by cytology, often requiring histological evaluation [7].

A bivariate plot of PTN/Tg and MDK/Tg showed strong clustering of PTC samples, such that all malignancies had MDK/Tg greater than 0.2 ng/mg and PTN/Tg greater than 0.13 ng/mg. Only 15% of benign nodules satisfied both these criteria (Fig 2B). The observation that the PTN/Tg ratio and the MDK/Tg ratio are elevated in PTC compared to benign nodules raises the possibility that measurement of PTN, MDK, and Tg in thyroid FNA samples might provide useful adjunctive diagnostic information to cytologic examination, as has been demonstrated by RNA profiling [23], mutational analysis [24] and other molecular approaches [25]. However, to establish a clinically useful approach, there are important challenges that would need to be overcome, many of which reflect limitations in the current study. First, to measure PTN in FNA washout, sufficient thyroid tissue must be present. Thus, a dedicated FNA pass, separate from those required for cytology, may be required to obtain sufficient tissue as is being done with the commercially available gene expression classifier test [23]. Alternative possible approaches include developing a more sensitive PTN assay or washing the expelled needle with a smaller volume of buffer and performing the assay without dilution. Second, the current



**Fig 3. Immunohistochemical staining for PTN.** A) Histological sections containing tall cell variant PTC were immunostained for PTN (brown color) and counterstained with hematoxylin (purple color). Immunohistochemical staining was more intense in the neoplastic thyroid epithelial cells within the PTCs (closed arrows) than in nearby normal thyroid epithelial cells (open arrows). Some stromal cells in the adjacent connective tissue also showed immunohistochemical staining. B) Higher magnification of PTC and normal tissue from the same section as in panel A. C) Immunohistochemical staining of classic PTC that shows perinuclear location of PTN (arrows). Size bar, 100  $\mu$ m.

doi:10.1371/journal.pone.0149383.g003

study was performed using FNA samples obtained *ex vivo* after thyroidectomy. Whether similar data would be observed with *in vivo*, percutaneous FNA sampling is unknown. We did not address this question because of the unavailability of dedicated *in vivo* FNA samples in this research study. Third, our approach may not be useful in patients with Graves' disease or chronic lymphocytic thyroiditis; we observed elevated PTN/Tg ratios in benign nodules within thyroid glands affected by these autoimmune disease. Fourth, adaptation of these findings into an adjunctive clinical diagnostic test would require a substantially larger study to determine the sensitivity and specificity in subjects with indeterminate cytology. The current pilot study demonstrates a novel observation of elevated PTN/Tg in all types of PTC, but was not designed to rigorously validate a diagnostic test. Our study is designed for a proof-of-concept and used *ex vivo* FNA materials. Therefore, ROC analysis is not performed.

## Conclusions

In conclusion, our findings indicate that PTN concentrations and the PTN/Tg ratio in *ex vivo* FNA samples distinguish PTC from benign lesions, raising the possibility that this strategy may have adjunctive diagnostic utility to supplement cytology and other existing molecular methods. However, additional larger studies would be needed to validate this approach.

## Supporting Information

**S1 Fig. Supplemental Figure 1A.** PTN cross-reactivity with MDK. **Supplemental Figure 1B.** MDK cross-reactivity with PTN. (DOCX)

**S2 Fig. Supplemental Figure 2A.** Stability in glass vs plastic tube. **Supplemental Figure 2B.** Stability at room temperature and during freeze and thaw cycle.  
(DOCX)

**S3 Fig. Supplemental Figure 3.** Parallelism of the PTN ELISA between the standard curve and serially diluted washout samples.  
(DOCX)

**S4 Fig. Supplemental Figure 4.** PTN concentrations were positively associated with Tg concentrations in FNA washout samples from benign nodules (analysis included all individual passes,  $R^2 = 0.04$ ,  $P < 0.001$ ).  
(DOCX)

**S5 Fig. Supplemental Figure 5.** Positive and negative IHC control.  
(DOCX)

**S1 Method. Supplemental Method.** Pleiotrophin Sandwich ELISA Assay.  
(DOCX)

## Author Contributions

Conceived and designed the experiments: YHJ LX MR DBS ATR AW EK JB. Performed the experiments: YHJ SMS LX. Analyzed the data: SMS FC LX MR AW EK. Contributed reagents/materials/analysis tools: YHJ SMS LX MR DBS ATR AW EK JB. Wrote the paper: YHJ SMS LX MR JB. Clinical evaluation of subjects and procurement of tissue samples: YHJ FSC EK. Revised the manuscript: YHJ FC DBS ATR AW EK JB.

## References

1. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. 2010. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules; AACE/AME/ETA Task Force on Thyroid Nodules. *Endocr Pract.* 16 Suppl 1:1–43. doi: [10.4158/10024.GL](https://doi.org/10.4158/10024.GL)
2. Tan GH, Gharib H. 1997. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. *Ann Intern Med.* 126:226–231. PMID: [9027275](https://pubmed.ncbi.nlm.nih.gov/9027275/)
3. Belfiore A, Giuffrida D, La Rosa GL, Ippolito O, Russo G, Fiumara A, et al. 1989. High frequency of cancer in cold thyroid nodules occurring at young age. *Acta Endocrinol (Copenh).* 121(2):197–202.
4. Castro MR, Gharib H. 2005. Continuing controversies in the management of thyroid nodules. *Ann Intern Med.* 7: 142(11):926–31. PMID: [15941700](https://pubmed.ncbi.nlm.nih.gov/15941700/)
5. Cooper DS, Doherty GM, Haugen BR. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* 19:1167 doi: [10.1089/thy.2009.0110](https://doi.org/10.1089/thy.2009.0110) PMID: [19860577](https://pubmed.ncbi.nlm.nih.gov/19860577/)
6. Mathur A, Olson MT, Zeiger MA. 2014. Follicular lesions of the thyroid. *Surg Clin North Am.* 94(3):499–513. doi: [10.1016/j.suc.2014.02.005](https://doi.org/10.1016/j.suc.2014.02.005) PMID: [24857573](https://pubmed.ncbi.nlm.nih.gov/24857573/)
7. Wu S, DeMay RM, Papas P, Yan B, Reeves W. 2012. Follicular lesions of the thyroid: a retrospective study of 1,348 fine needle aspiration biopsies. *Diagn Cytopathol.* 40 Suppl 1:E8–12. doi: [10.1002/dc.21477](https://doi.org/10.1002/dc.21477) PMID: [20954270](https://pubmed.ncbi.nlm.nih.gov/20954270/)
8. Tsutsui J, Uehara K, Kadomatsu K, Matsubara S, Muramatsu T. 1991. A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse. *Biochem Biophys Res Commun.* 30: 176(2):792–7. PMID: [2025291](https://pubmed.ncbi.nlm.nih.gov/2025291/)
9. Nakamoto M, Matsubara S, Miyauchi T, Obama H, Ozawa M, Muramatsu T. 1992. A new family of heparin binding growth/differentiation factors: differential expression of the midkine (MK) and HB-GAM genes during mouse development. *J Biochem.* 112(3):346–9. PMID: [1343086](https://pubmed.ncbi.nlm.nih.gov/1343086/)
10. Sakamoto K, Kadomatsu K. 2012. Midkine in the pathology of cancer, neural disease, and inflammation. *Pathol Int.* 62(7):445–55. doi: [10.1111/j.1440-1827.2012.02815.x](https://doi.org/10.1111/j.1440-1827.2012.02815.x) PMID: [22726064](https://pubmed.ncbi.nlm.nih.gov/22726064/)

11. Papadimitriou E, Mikelis C, Lampropoulou E, Koutsoumpa M, Theochari K, Tsirmoula S, et al. 2009. Roles of pleiotrophin in tumor growth and angiogenesis. *Eur Cytokine Netw* 20(4):180–90. doi: [10.1684/ecn.2009.0172](https://doi.org/10.1684/ecn.2009.0172) PMID: [20167557](https://pubmed.ncbi.nlm.nih.gov/20167557/)
12. Jee YH, Celi FS, Sampson M, David BS, Remaley AT, Kebebew E, et al. 2014. Midkine Concentrations in Fine-Needle Aspiration of Benign and Malignant Thyroid Nodules. *Clin Endocrinol (Oxf)*. In press.
13. Ameer N, Lacroix L, Roucan S, Roux V, Broutin S, Talbot M, et al. 2009. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. *Endocr Relat Cancer*. 16(4):1261–72. doi: [10.1677/ERC-08-0289](https://doi.org/10.1677/ERC-08-0289) PMID: [19675075](https://pubmed.ncbi.nlm.nih.gov/19675075/)
14. Fuhrer D, Eszlinger M, Karger S, Krause K, Engelhardt C, Hasenclever D, Dralle H, Paschke R. Evaluation of insulin-like growth factor II, cyclooxygenase-2, ets-1 and thyroid-specific thyroglobulin mRNA expression in benign and malignant thyroid tumours. *Eur J Endocrinol*. 2005 May; 152(5):785–90. PMID: [15879365](https://pubmed.ncbi.nlm.nih.gov/15879365/)
15. Erlandsen H, Ames JE, Tamkenath A, Mamaeva O, Stidham K, Wilson ME, et al. 2012. Pleiotrophin expression during odontogenesis. *J Histochem Cytochem*. 60(5):366–75. doi: [10.1369/0022155412439316](https://doi.org/10.1369/0022155412439316) PMID: [22382872](https://pubmed.ncbi.nlm.nih.gov/22382872/)
16. Adthapanyawanich K, Yamamoto M, Wakayama T, Nakata H, Keattikunpairoj S, Iseki S. 2013. Expression and localization of receptor protein tyrosine phosphatase  $\beta$  and its ligand pleiotrophin in the submandibular gland of mice. *Arch Oral Biol*. 58(2):181–91. PMID: [23092607](https://pubmed.ncbi.nlm.nih.gov/23092607/)
17. Sethi G, Kwon Y, Burkhalter RJ, Pathak HB, Madan R, McHugh S, et al. 2014. PTN signaling: Components and mechanistic insights in human ovarian cancer. *Mol Carcinog*. In Press.
18. Weber D, Klomp HJ, Czubyko F, Wellstein A, Juhl H. 2000. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. *Cancer Res*. 15; 60(18):5284–8. PMID: [11016659](https://pubmed.ncbi.nlm.nih.gov/11016659/)
19. Koyama-Nasu R, Haruta R, Nasu-Nishimura Y, Taniue K, Katou Y, Shirahige K, et al. 2014. The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells. *Oncogene*. 24; 33(17):2236–44. doi: [10.1038/onc.2013.168](https://doi.org/10.1038/onc.2013.168) PMID: [23686309](https://pubmed.ncbi.nlm.nih.gov/23686309/)
20. Tsirmoula S, Dimas K, Hatzia Apostolou M, Lamprou M, Ravazoula P, Papadimitriou E. 2012. Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo. *Cancer Sci*. 103(10):1826–32. doi: [10.1111/j.1349-7006.2012.02383.x](https://doi.org/10.1111/j.1349-7006.2012.02383.x) PMID: [22783964](https://pubmed.ncbi.nlm.nih.gov/22783964/)
21. Wellstein A, Fang WJ, Khatri A, Lu Y, Swain SS, Dickson RB, et al. 1992. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. *J Biol Chem*. 5; 267(4):2582–7. PMID: [1733956](https://pubmed.ncbi.nlm.nih.gov/1733956/)
22. Chang Y, Zuka M, Perez-Pinera P, Astudillo A, Mortimer J, Berenson JR, et al. 2007. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. *Proc Natl Acad Sci U S A*. 26; 104(26):10888–93. PMID: [17578909](https://pubmed.ncbi.nlm.nih.gov/17578909/)
23. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. 2012. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. *N Engl J Med*. 23; 367(8):705–15. doi: [10.1056/NEJMoa1203208](https://doi.org/10.1056/NEJMoa1203208) PMID: [22731672](https://pubmed.ncbi.nlm.nih.gov/22731672/)
24. Rossi M, Buratto M, Tagliati F, Rossi R, Lupo S, Trasforini G, et al. 2015. Relevance of BRAFV600E Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer. *Thyroid*. 25(2):221–8 doi: [10.1089/thy.2014.0338](https://doi.org/10.1089/thy.2014.0338) PMID: [25333496](https://pubmed.ncbi.nlm.nih.gov/25333496/)
25. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, et al. 2012. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. *Thyroid*. 22(3):285–91. doi: [10.1089/thy.2011.0313](https://doi.org/10.1089/thy.2011.0313) PMID: [22304369](https://pubmed.ncbi.nlm.nih.gov/22304369/)